115 related articles for article (PubMed ID: 18069612)
1. [Targeted therapy for cancer: anti-tyrosine kinase receptor agents].
García ED
An R Acad Nac Med (Madr); 2007; 124(1):171-84; discussion 184-8. PubMed ID: 18069612
[TBL] [Abstract][Full Text] [Related]
2. [Molecular targeted therapy in colorectal cancer].
Ree AH; Bratland A; Dueland S
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):190-3. PubMed ID: 18202731
[TBL] [Abstract][Full Text] [Related]
3. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
4. [The place of targeted treatments: receptor tyrosine kinase inhibitors].
Bréchot JM
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S68-71. PubMed ID: 15536357
[TBL] [Abstract][Full Text] [Related]
5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
6. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.
Lee KI; Park Y; Park SJ; Hwang JH; Lee SJ; Kim GD; Park WK; Lee S; Jeong D; Kong JY; Kang HK; Cho H
Bioorg Med Chem Lett; 2006 Feb; 16(3):737-42. PubMed ID: 16321529
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
11. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
12. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
13. [Role of predictive pathology in oncology--example of new therapies targeting EGFR].
Hartmann A
Verh Dtsch Ges Pathol; 2006; 90():128-35. PubMed ID: 17867589
[TBL] [Abstract][Full Text] [Related]
14. EGFR targeting of solid tumors.
Rocha-Lima CM; Soares HP; Raez LE; Singal R
Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
[TBL] [Abstract][Full Text] [Related]
15. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
16. Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family.
Teller N; Thiele W; Boettler U; Sleeman J; Marko D
Mol Nutr Food Res; 2009 Sep; 53(9):1075-83. PubMed ID: 19653223
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
18. [New molecules for therapeutic targets in cancer].
L'Allemain G; Bénard J
Bull Cancer; 2001 Dec; 88(12):1240-5. PubMed ID: 11792617
[No Abstract] [Full Text] [Related]
19. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
20. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
